De-identified Health Data Market Size & Growth Forecast 2026–2035, By Segments (Type of Data, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

De-identified Health Data Market size was assessed at USD 8.6 Billion in 2025 and is poised to grow at a 9.2% CAGR between 2026 and 2035, reaching USD 20.74 Billion by 2035. The industry revenue for 2026 is calculated at USD 9.29 billion.

• Base Year Value (2025): USD 8.6 Billion
• CAGR (2026-2035): 9.2%
• Forecast Year Value (2035): USD 20.74 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

De-identified Health Data Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 37.42% of the market in 2025, driven by advanced healthcare IT infrastructure, widespread electronic health record adoption, and strong demand for compliant secondary data use.
  • Asia Pacific is expected to expand at a 10.4% CAGR as healthcare digitization, electronic records adoption, and growing use of analytics generate more de-identified data for research and commercial applications.

• Segment Momentum:

  • Clinical Data accounted for an 18.81% share in 2025 because it is consistently generated, well-structured, and widely used for care delivery, outcomes analysis, population health management, and operational benchmarking.
  • Pharmaceutical Companies are the fastest-growing end users as they increasingly rely on de-identified health data to support trial design, patient stratification, safety monitoring, and real-world evidence generation across product development.

• Market Expansion Drivers:

  • Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets.
  • Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research.
  • Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics.

• Leading Market Participants:

  Major companies in the de-identified health data market include IQVIA Inc. (United States), Oracle Corporation (United States), UnitedHealth Group (Optum) (United States), ICON plc (Ireland), IBM Corporation (United States), Komodo Health Inc. (United States), Dassault Systèmes (Medidata Solutions) (France), Premier Inc. (United States), Flatiron Health (United States), Veradigm LLC (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 8.6 Billion
  • Projected Market Size: USD 20.74 Billion by 2035
  • Growth Forecasts: 9.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Clinical Data (Type of Data) | Healthcare Providers (End-use) | Clinical Research and Trials (Application)
  • Emerging Opportunity Segment: Genomic Data (Type of Data) | Pharmaceutical Companies (End-use) | Drug Discovery and Development (Application)

Market Growth Drivers and Industry Trends

Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets

As healthcare providers, life sciences companies, and digital health platforms deploy AI models for diagnosis support, risk stratification, and workflow optimization, they require large volumes of structured and diverse patient data that can be used without exposing personal identifiers. This is driving demand for the de-identified health data market because model development depends on access to longitudinal clinical records, imaging, outcomes data, and treatment histories that remain usable under privacy and governance requirements. In practice, organizations are purchasing and licensing de-identified datasets to shorten data acquisition cycles, reduce compliance friction, and make AI training pipelines more scalable, which is strengthening market development around high-quality, regulation-aligned data assets.

Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research

The rapid accumulation of data from electronic health records and connected health devices is widening the pool of patient-level information available for retrospective analysis, outcomes research, and population health studies. For the de-identified health data market, this creates a larger and more varied supply of usable datasets, while also increasing demand from researchers and commercial teams seeking real-world evidence beyond controlled clinical environments. The practical effect is a shift toward curated de-identified data products that combine clinical, behavioral, and monitoring data into research-ready formats, aiding market expansion by making secondary healthcare research faster, broader in scope, and more operationally feasible.

Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics

Efforts to combine data from hospitals, research centers, diagnostic laboratories, and biopharma organizations are increasing the need for standardized, privacy-protected information that can move across institutional boundaries without triggering patient confidentiality concerns. This is influencing adoption in the de-identified health data market because personalized medicine and advanced diagnostics depend on broad, heterogeneous datasets that capture variations in genetics, treatment response, disease progression, and clinical context. As collaborations become more central to biomarker discovery and diagnostic model validation, demand is rising for de-identified datasets that are interoperable, linkable, and governed for multi-party use, reinforcing market demand for specialized data curation and access solutions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets	2.00%	High	North America, Europe	High	Near Term
Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research	1.80%	Moderate	North America, Asia Pacific	High	Mid Term
Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics	1.50%	High	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in the de-identified health data market in 2025, accounting for a 37.42% share. Its leadership is backed by the concentration of advanced healthcare IT infrastructure, widespread use of electronic health records, and strong demand from pharmaceutical, payer, provider, and research organizations that rely on large, structured datasets for clinical development, population health analysis, and operational decision-making. The region’s mature data management environment also helps sustain market activity, as organizations are better equipped to aggregate, standardize, and commercialize de-identified datasets for compliant secondary use.

Asia Pacific is projected to expand at a 10.4% CAGR over the forecast period in the de-identified health data market, driven by the rapid digitization of healthcare systems and rising data generation across hospitals, diagnostic networks, and public health platforms. Growth is accelerating as more healthcare providers adopt digital records and analytics tools, creating a larger base of usable patient information that can be processed into de-identified formats for research and commercial applications. Increasing interest in data-led healthcare planning and broader adoption of health technology across developing and developed markets in the region are also boosting practical demand for scalable data utilization models.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Emerging	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Stable	Weak

Key Country Insights

United States

Research Data Commercialization

The U.S. continues to expand the use of de-identified health data across clinical research, life sciences, and artificial intelligence development. Organizations prioritize secure data governance frameworks that enable responsible data sharing while maintaining regulatory compliance and research value.

Japan

Healthcare Analytics Enablement

Japan is advancing the use of de-identified health data to strengthen healthcare analytics, medical research, and digital health innovation. Data custodians increasingly focus on high-quality datasets that support evidence generation while protecting patient confidentiality.

South Korea

AI Data Infrastructure

South Korea is expanding de-identified health data initiatives to accelerate healthcare artificial intelligence and precision medicine applications. Organizations prioritize secure data integration platforms that facilitate research collaboration while meeting evolving governance expectations.

Germany

Privacy-Centered Data Exchange

Germany emphasizes de-identified health data solutions that balance research collaboration with rigorous privacy and data protection requirements. Healthcare institutions increasingly invest in standardized anonymization practices to support trusted clinical and scientific data sharing.

France

Clinical Research Collaboration

France continues to strengthen the availability of de-identified health data for academic and clinical research initiatives. Healthcare organizations emphasize interoperable data management practices that improve research accessibility while preserving patient privacy and regulatory alignment.

Italy

Digital Health Integration

Italy is increasing the use of de-identified health data to support healthcare digitalization and evidence-based decision-making. Institutions focus on improving data standardization and secure information exchange to strengthen collaboration across clinical research and healthcare delivery.

Segment Leadership and Growth Trends

  Type of Data Segment Analysis: Clinical Data (Largest Segment) vs Genomic Data (Fastest-Growing Segment)

Clinical Data held the leading position in the de-identified health data market in 2025, accounting for an 18.81% share. Its leadership is maintained through the broad usability of clinical records across care delivery, outcomes analysis, population health management, and operational benchmarking. In the de-identified health data market, clinical data remains the most consistently generated and readily structured dataset within healthcare systems, making it easier for data users to integrate into routine analytics, payer evaluation, and provider performance assessment workflows.

Genomic Data is emerging as the fastest-growing segment in the de-identified health data market as precision medicine and biomarker-driven research create stronger demand for highly specific patient-level insights. Its momentum is being driven by the growing need to connect molecular patterns with treatment response, especially in drug discovery and targeted therapy development. Compared with more established data types, genomic data is seeing wider adoption because it supports newer research and clinical decision models that depend on deeper biological stratification rather than broad retrospective utilization patterns.

End-use Segment Analysis: Healthcare Providers (Largest Segment) vs Pharmaceutical Companies (Fastest-Growing Segment)

By 2025, Healthcare Providers represented the largest share of the de-identified health data market. Their leading position reflects direct control over large volumes of patient data generated through everyday clinical activity, including diagnoses, treatments, outcomes, and care pathways. This sustained access to continuous real-world information allows providers to remain central participants in the de-identified health data market, particularly as demand remains strong for datasets that reflect actual clinical practice and longitudinal patient interactions.

Pharmaceutical Companies are the fastest-growing end-use segment in the de-identified health data market, driven by the increasing use of real-world evidence in research, development, and post-market evaluation. Their growth is closely tied to the need for broader and more diverse datasets that can support trial design, patient stratification, safety monitoring, and commercial evidence generation. Relative to other end users, pharmaceutical companies are expanding their use of de-identified health data more rapidly because they are under growing pressure to improve development efficiency and demonstrate treatment value across the product lifecycle.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type of Data	Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data, Laboratory Data, Social Determinants of Health (SDoH) Data, Pharmacogenomic Data, Biometric Data, Operational and Financial Data, Epidemiological Data, Healthcare Utilization Data, Others	Clinical Data	Genomic Data
End-use	Pharmaceutical Companies, Biotechnology Firms, Medical Device Manufacturers, Healthcare Providers, Research Institutions, Others	Healthcare Providers	Pharmaceutical Companies
Application	Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, Market Access and Commercial Strategy, Business Intelligence and Operational Efficiency, Telemedicine and Remote Monitoring, Patient Engagement and Support Programs, Others	Clinical Research and Trials	Drug Discovery and Development

Competitive Landscape and Market Positioning

Top players in the de-identified health data market:

1. IQVIA Inc. (United States)

2. Oracle Corporation (United States)

3. UnitedHealth Group (Optum) (United States)

4. ICON plc (Ireland)

5. IBM Corporation (United States)

6. Komodo Health Inc. (United States)

7. Dassault Systèmes (Medidata Solutions) (France)

8. Premier Inc. (United States)

9. Flatiron Health (United States)

10. Veradigm LLC (United States)

Increasing reliance on data-driven healthcare insights is accelerating growth in the de-identified health data market. Organizations are implementing advanced anonymization technologies, AI-powered analytics, and interoperable data platforms to support research, population health management, and clinical innovation. Strategic collaborations focused on secure data sharing and compliance optimization are also strengthening the value of de-identified healthcare datasets.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
M&A Activity / Consolidation Trend	Active	Frequent acquisitions and partnerships, such as Datavant’s merger with Ciox in 2021, drive consolidation.
Market Concentration	Low	Fragmented with players like IQVIA and HealthVerity; no single dominant firm due to diverse offerings.
Degree of Product Differentiation	High	Platforms vary in data aggregation, AI analytics, and compliance with HIPAA/GDPR standards.
Competitive Advantage Sustainability	Eroding	Rapid tech advancements and regulatory changes challenge early movers’ advantages.
Innovation Intensity	High	AI-driven analytics and blockchain for data security fuel rapid development.
Customer Loyalty / Stickiness	Weak	Clients switch based on data quality, cost, and compliance with evolving regulations.
Vertical Integration Level	Low	Providers focus on data processing, relying on external sources for raw data and tech platforms.

Industry Development/News

Company Name	Date	Key Development
NHS	Feb-26	The UK government has mandated the development of technical infrastructure for the NHS to facilitate the use of anonymized primary care patient data for research. This initiative aims to establish a secure, large-scale framework for data sharing, enabling expanded access to national health datasets for medical and public health research while enforcing rigorous de-identification standards.
ICON	Sep-24	ICON entered a strategic collaboration with Intel to leverage de-identified data from its clinical research platform alongside Intel's AI technology. The partnership focuses on optimizing patient recruitment and streamlining clinical trial workflows, utilizing large-scale data insights to improve precision medicine and increase overall efficiency in the drug development pipeline.
Amazon Web Services	Nov-25	The government of La Rioja, through Fundación Rioja Salud, launched the PASCAL health data lake on Amazon Web Services infrastructure. This cloud-based platform consolidates health data into a unified environment to support predictive, preventive, and precision medicine, providing the analytical capacity required for data-driven healthcare innovation and large-scale clinical research applications.
Seqster	Mar-24	The Multiple Sclerosis Implementation Network adopted the Seqster operating system to standardize health data sharing and management for neurological research. The platform facilitates the integration and coordination of patient data across diverse stakeholders, improving research workflow efficiency and enabling evidence-based clinical decision-making within the treatment of multiple sclerosis.
Great Ormond Street Hospital	Feb-26	The Great Ormond Street Hospital for Children NHS Foundation Trust partnered with a charitable entity to integrate pediatric health data for rare disease research. This initiative focuses on improving data linkage and accessibility across clinical and research systems, enhancing collaborative capabilities to support the analysis of rare conditions and advance pediatric healthcare outcomes.
UK Biobank	Mar-26	The accidental disclosure of volunteers’ de-identified health data by researchers has highlighted critical governance challenges in the management of large-scale biomedical repositories. This incident underscores ongoing operational risks and the necessity for enhanced privacy safeguards and stricter access control frameworks for researchers utilizing distributed secondary health datasets.